
The first and only oral treatment for carcinoid syndrome diarrhea^1,2 XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Dear Dr. {{accLname}},

I am excited to introduce XERMELO, the first and only tryptophan hydroxylase inhibitor, a new treatment for patients with carcinoid syndrome diarrhea.^1,2

XERMELO is now available by prescription in a 250‑mg oral tablet.

Through inhibition of tryptophan hydroxylase, XERMELO decreases the production of serotonin and the frequency of carcinoid syndrome diarrhea.^1,2

XERMELO, administered at 250 mg 3 times daily with food, was evaluated in a 12-week, multicenter, Phase III, randomized, placebo-controlled trial of XERMELO + SSA (n=45) vs SSA alone (n=45).¹


IN THIS STUDY

•

At 6 and 12 weeks, 24-hour u5-HIAA levels decreased with XERMELO + SSA but not with SSA alone¹

•

89% of patients receiving XERMELO + SSA experienced improvement in bowel-movement frequency vs 69% of patients receiving SSA alone¹

•

XERMELO + SSA provided significant and superior reductions in daily bowel movements averaged over 12 weeks (–1.4 with XERMELO 250 mg + SSA vs –0.6 with SSA alone; P<0.001) (primary endpoint)¹

•

XERMELO + SSA provided early and sustained reductions in bowel-movement frequency, observed as early as 1 to 3 weeks and maintained throughout the 12‑week study¹

•

The most common adverse reactions (≥5%) include nausea, headache, increased gamma-glutamyl-transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia¹

SSA=somatostatin analog; u5-HIAA=urinary 5-hydroxyindoleacetic acid.

Read the press release detailing the FDA approval of XERMELO.

Today marks an important leap forward in adding a new treatment option for patients suffering from carcinoid syndrome diarrhea. On behalf of Lexicon, I thank you for the critical role you serve as a key member of the patient care team helping to improve the lives of patients managing the effects of this disease.

Lexicon is committed to simplifying access to XERMELO and to improving a patient's chance for a successful clinical outcome. To that end, we've developed LexCares, a comprehensive program providing information and tools to help patients access the medication they need. Visit LexCares to complete the Enrollment Form now.

I look forward to meeting with you and your staff to discuss how XERMELO may be an appropriate option for your patients with carcinoid syndrome. If you have any questions, please feel free to contact me by replying to this email.

Important Safety Information

Warnings and Precautions: XERMELO may cause constipation, which can be serious. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.

Learn more about XERMELO and view the
full Prescribing Information at www.XERMELO.com.

Important Safety Information (continued)

Adverse Reactions: The most common adverse reactions (≥5%) include nausea, headache, increased gamma-glutamyl-transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia.

Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 substrates, as XERMELO may decrease their systemic exposure.

For more information about XERMELO, please see full Prescribing Information.

Sincerely,
{{userName}}

References: 1. XERMELO Prescribing Information. The Woodlands, TX: Lexicon Pharmaceuticals, Inc.; February 2017. 2. Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Oncologist. 2016;21:701-707.

This email is intended for US healthcare professionals only.

To unsubscribe from Lexicon Pharmaceuticals, Inc. communications, click here.

Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands, TX 77381-1160